NBI‐98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double‐blind, placebo‐controlled study

BACKGROUND: Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI‐98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6‐week, double‐blind, placebo‐controlled, dose‐titration study evaluating...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Brien, Christopher F., Jimenez, Roland, Hauser, Robert A., Factor, Stewart A., Burke, Joshua, Mandri, Daniel, Castro‐Gayol, Julio C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049616/
https://www.ncbi.nlm.nih.gov/pubmed/26346941
http://dx.doi.org/10.1002/mds.26330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049616/
https://www.ncbi.nlm.nih.gov/pubmed/26346941
http://dx.doi.org/10.1002/mds.26330

Ejemplares similares